Bath & Body Works, Inc. (NYSE:BBWI – Get Free Report) Director Lucy Brady acquired 3,470 shares of the business’s stock in a transaction on Friday, November 21st. The stock was purchased at an average cost of $14.40 per share, with a total value of $49,968.00. Following the acquisition, the director directly owned 17,482 shares of the company’s stock, valued at $251,740.80. This represents a 24.76% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Bath & Body Works Stock Up 4.9%
Shares of BBWI stock traded up $0.73 during mid-day trading on Monday, hitting $15.58. 18,351,475 shares of the stock were exchanged, compared to its average volume of 5,908,003. Bath & Body Works, Inc. has a 52-week low of $14.27 and a 52-week high of $41.87. The company has a market cap of $3.21 billion, a PE ratio of 4.62, a price-to-earnings-growth ratio of 0.86 and a beta of 1.53. The firm has a fifty day moving average of $24.58 and a 200 day moving average of $28.11.
Bath & Body Works (NYSE:BBWI – Get Free Report) last released its quarterly earnings results on Thursday, November 20th. The company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.05). Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period in the previous year, the company posted $0.49 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. Bath & Body Works has set its FY 2025 guidance at 2.870- EPS. Q4 2025 guidance at 1.700- EPS. Equities analysts predict that Bath & Body Works, Inc. will post 3.3 EPS for the current year.
Bath & Body Works Announces Dividend
Institutional Trading of Bath & Body Works
A number of hedge funds and other institutional investors have recently modified their holdings of BBWI. T. Rowe Price Investment Management Inc. increased its position in shares of Bath & Body Works by 7.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 11,016,767 shares of the company’s stock valued at $334,029,000 after acquiring an additional 781,681 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Bath & Body Works by 11.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,080,106 shares of the company’s stock worth $212,120,000 after purchasing an additional 733,000 shares during the period. Alliancebernstein L.P. boosted its position in shares of Bath & Body Works by 2.2% during the 3rd quarter. Alliancebernstein L.P. now owns 5,861,444 shares of the company’s stock worth $150,991,000 after purchasing an additional 123,648 shares during the period. Cooper Creek Partners Management LLC increased its holdings in Bath & Body Works by 42.7% in the 2nd quarter. Cooper Creek Partners Management LLC now owns 5,409,919 shares of the company’s stock valued at $162,081,000 after purchasing an additional 1,619,276 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in Bath & Body Works by 2,204.1% during the third quarter. American Century Companies Inc. now owns 5,174,370 shares of the company’s stock worth $133,292,000 after purchasing an additional 4,949,796 shares in the last quarter. 95.14% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have commented on BBWI shares. Wells Fargo & Company reduced their target price on Bath & Body Works from $33.00 to $25.00 and set an “overweight” rating for the company in a report on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bath & Body Works in a research report on Wednesday, October 8th. Morgan Stanley reissued an “equal weight” rating and issued a $18.00 price objective (down from $43.00) on shares of Bath & Body Works in a research note on Friday. The Goldman Sachs Group cut shares of Bath & Body Works from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $39.00 to $17.00 in a research note on Thursday. Finally, Baird R W lowered shares of Bath & Body Works from a “strong-buy” rating to a “hold” rating in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $26.84.
Check Out Our Latest Stock Analysis on BBWI
Bath & Body Works Company Profile
Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Recommended Stories
- Five stocks we like better than Bath & Body Works
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- The 3 Best Blue-Chip Stocks to Buy Now
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
- How to Buy Cheap Stocks Step by Step
- JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.
